

ECTRIMS/EAN Guideline on the pharmacological treatment of multiple sclerosis

Multiple Sclerosis Journal

24, 96-120

DOI: [10.1177/1352458517751049](https://doi.org/10.1177/1352458517751049)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. <i>Neurology</i> , 2018, 90, 1106-1112.	1.5	15
2	Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night. <i>Multiple Sclerosis Journal</i> , 2018, 24, 558-562.	1.4	5
3	Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 203-219.	1.4	8
4	Commentary on theECTRIMSâ€“EAN guideline for pharmacological treatment of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641877037.	1.5	2
5	Multiple sclerosis. <i>Lancet</i> , The, 2018, 391, 1622-1636.	6.3	1,204
7	BewÃ¤ltigung und Umgang mit chronischen Krankheiten. <i>The Studium Pflege</i> , 2018, , 1-11.	0.1	0
8	Multiple sclerosis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 43.	18.1	767
9	2018 Editorsâ€™ commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1394-1395.	1.4	0
10	European and American Guidelines for Multiple Sclerosis Treatment. <i>Neurology and Therapy</i> , 2018, 7, 189-194.	1.4	45
11	The Role of Prescribing Generic (Non-proprietary) Drugs in the Prevalence of Therapeutic Inertia in Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018, 9, 835.	1.1	6
12	Early versus later treatment start in multiple sclerosis: a registerâ€“based cohort study. <i>European Journal of Neurology</i> , 2018, 25, 1262.	1.7	60
13	Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. , 2018, , 1-103.		0
14	Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018, 9, 522.	1.1	3
15	A case for gender-based approach to multiple sclerosis therapeutics. <i>Frontiers in Neuroendocrinology</i> , 2018, 50, 123-134.	2.5	19
16	Disease-Modifying Therapies for Relapsingâ€“Remitting Multiple Sclerosis: A Network Meta-Analysis. <i>CNS Drugs</i> , 2018, 32, 813-826.	2.7	50
17	Integrating multiple sclerosis guidelines into practice. <i>Lancet Neurology</i> , The, 2018, 17, 658-660.	4.9	5
18	Pediatric multiple sclerosis and fulminant disease course: Features and approaches to treatment â€“ A case report and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2018, 53, 13-19.	0.8	4
19	Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2018, 32, 939-949.	2.7	69

#	ARTICLE	IF	CITATIONS
20	Cladribine Tablets: A Review in Relapsing MS. <i>CNS Drugs</i> , 2018, 32, 785-796.	2.7	44
21	The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. <i>Global & Regional Health Technology Assessment</i> , 2019, 2019, 228424031983852.	0.2	2
22	Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?. <i>Neurology and Therapy</i> , 2019, 8, 177-184.	1.4	5
23	<p>Comorbidities in multiple sclerosis"a plea for interdisciplinary collaboration to improve the quality of life of MS patients</p>. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2019, Volume 9, 39-53.	0.7	4
24	Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression. <i>Neurology and Therapy</i> , 2019, 8, 185-205.	1.4	14
25	Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care. <i>MDM Policy and Practice</i> , 2019, 4, 238146831985564.	0.5	6
26	Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain. <i>JAMA Network Open</i> , 2019, 2, e197093.	2.8	18
27	Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 973-980.	4.9	99
28	Head-to-head drug comparisons in multiple sclerosis. <i>Neurology</i> , 2019, 93, 793-809.	1.5	20
29	Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. <i>CNS Drugs</i> , 2019, 33, 1087-1099.	2.7	19
30	Editorial. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1335-1336.	1.4	3
31	A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. <i>MDM Policy and Practice</i> , 2019, 4, 238146831987913.	0.5	2
32	An Update on Vitamin D and Disease Activity in Multiple Sclerosis. <i>CNS Drugs</i> , 2019, 33, 1187-1199.	2.7	59
33	The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View. <i>Cells</i> , 2019, 8, 1280.	1.8	28
34	Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 857-873.	1.0	11
35	Historical and Current Concepts Regarding Urodynamics in Multiple Sclerosis Patients. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 168-173.	0.2	1
36	Anti-thyroid autoantibodies as biomarkers for alemtuzumab associated thyroid autoimmunity. <i>EBioMedicine</i> , 2019, 47, 22-23.	2.7	2
37	Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. <i>PLoS ONE</i> , 2019, 14, e0222012.	1.1	14

#	ARTICLE	IF	CITATIONS
38	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019, 266, 3098-3107.	1.8	1
39	Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101406.	0.9	3
40	Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. <i>Clinical Drug Investigation</i> , 2019, 39, 331-340.	1.1	15
41	Trends In Coverage For Disease-Modifying Therapies For Multiple Sclerosis In Medicare Part D. <i>Health Affairs</i> , 2019, 38, 303-312.	2.5	18
42	Pharmacoeconomics of synthetic therapies for multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1331-1340.	0.9	8
43	<p>Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1439-1457.	1.0	9
44	Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments. <i>Paediatric Drugs</i> , 2019, 21, 137-152.	1.3	5
45	Long term effects of corticosteroids in multiple sclerosis in terms of the "no evidence of disease activity" (NEDA) domains. <i>Steroids</i> , 2019, 149, 108401.	0.8	1
46	The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 51-54.	0.9	4
47	Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 157-164.	0.9	16
48	Towards a standard MRI protocol for multiple sclerosis across the UK. <i>British Journal of Radiology</i> , 2019, 92, 20180926.	1.0	9
49	Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. <i>Journal of Central Nervous System Disease</i> , 2019, 11, 117957351983199.	0.7	15
50	Navigating choice in multiple sclerosis management. <i>Neurological Research and Practice</i> , 2019, 1, 5.	1.0	10
51	Initiating disease-modifying treatments in multiple sclerosis: Measuring the decision process using decisional conflict and decisional regret scales. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731983300.	0.5	5
52	Real-Life Outcome in Multiple Sclerosis in the Czech Republic. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-8.	0.4	6
53	The monoclonal antibody GNBAC1: targeting human endogenous retroviruses in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641983357.	1.5	26
54	Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate. <i>Journal of the Neurological Sciences</i> , 2019, 401, 43-50.	0.3	5
55	Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2019, 15, 287-300.	4.9	167

#	ARTICLE	IF	CITATIONS
56	Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 54-63.	0.9	37
57	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 845-854.	2.0	69
58	Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 104-109.	0.9	1
59	German translation, cultural adaption and validation of the unidimensional self-efficacy scale for multiple sclerosis: a study protocol. <i>BMJ Open</i> , 2019, 9, e029565.	0.8	3
60	Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2019, 16, 228.	3.1	30
61	Actualisation des aspects cliniques et des critères diagnostiques de la sclérose en plaques. <i>Pratique Neurologique - FMC</i> , 2019, 10, 118-125.	0.1	0
62	Diagnosis and management of secondary-progressive multiple sclerosis: time for change. <i>Neurodegenerative Disease Management</i> , 2019, 9, 301-317.	1.2	22
63	Dimethyl Fumarate: A Review in Relapsing-Remitting MS. <i>Drugs</i> , 2019, 79, 1965-1976.	4.9	65
64	Mutually reinforcing effects of genetic variants and interferon- β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. <i>Pulmonary Circulation</i> , 2019, 9, 1-6.	0.8	9
65	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. <i>Current Opinion in Neurology</i> , 2019, 32, 365-377.	1.8	73
66	MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 138-144.	0.9	4
67	A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis. <i>Autoimmunity Reviews</i> , 2019, 18, 255-261.	2.5	45
68	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
69	Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 261-267.	0.9	22
70	Patterns of care for Multiple Sclerosis in a setting of universal care access: A cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 17-25.	0.9	14
71	Multiple sclerosis – a review. <i>European Journal of Neurology</i> , 2019, 26, 27-40.	1.7	1,057
72	Treatment of multiple sclerosis – success from bench to bedside. <i>Nature Reviews Neurology</i> , 2019, 15, 53-58.	4.9	239
73	Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 295-303.	0.7	8

#	ARTICLE	IF	CITATIONS
74	Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. <i>Journal of Neurology</i> , 2020, 267, 3489-3498.	1.8	82
75	Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1227-1236.	1.4	12
76	Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 659-667.	1.4	27
77	Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101452.	0.9	57
79	MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. <i>European Journal of Neurology</i> , 2020, 27, 429-436.	1.7	39
80	Factors associated with therapeutic inertia among pharmacists caring for people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101887.	0.9	2
81	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β -1a. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101891.	0.9	4
82	Precision Medicine in Neurodegenerative Diseases: Some Promising Tips Coming from the microRNAs World. <i>Cells</i> , 2020, 9, 75.	1.8	10
83	Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany. <i>Neurology and Therapy</i> , 2020, 9, 67-83.	1.4	10
84	Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 67-74.	0.9	15
85	An argument for broad use of high efficacy treatments in early multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	47
86	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 23-37.	1.4	55
87	The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 637-645.	1.1	14
88	The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642095411.	1.5	3
89	Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1255-1274.	0.6	44
90	Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102503.	0.9	8
91	Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642095107.	1.5	18
92	Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. <i>BMC Neurology</i> , 2020, 20, 281.	0.8	41

#	ARTICLE	IF	CITATIONS
93	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 914-920.	0.9	5
94	The impact of the face-to-face consultation on decisional conflict in complex decision-making in multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732095980.	0.5	2
95	The Crotoxin:SBA-15 Complex Down-Regulates the Incidence and Intensity of Experimental Autoimmune Encephalomyelitis Through Peripheral and Central Actions. <i>Frontiers in Immunology</i> , 2020, 11, 591563.	2.2	5
96	New insights into the socio-economic aspects of multiple sclerosis in a cohort of Polish patients. <i>Annals of Agricultural and Environmental Medicine</i> , 2020, 28, 99-106.	0.5	3
97	Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102435.	0.9	3
98	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	3.7	56
99	Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. <i>BMC Neurology</i> , 2020, 20, 296.	0.8	23
100	The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102554.	0.9	2
101	Siponimod: A Review in Secondary Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2020, 34, 1191-1200.	2.7	42
102	Importance of early treatment decisions on future income of multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732095911.	0.5	6
103	Structured Reporting in Multiple Sclerosis Reduces Interpretation Time. <i>Academic Radiology</i> , 2021, 28, 1733-1738.	1.3	4
104	Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102461.	0.9	8
105	Multiple sclerosis and nutrition: back to the future?. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	1.5	2
106	An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2020, 10, 369-382.	1.2	13
107	An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014 to 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102521.	0.9	20
108	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
109	Outcome measures for disease-modifying therapies in relapsing multiple sclerosis randomized clinical trials. <i>JBI Evidence Synthesis</i> , 2020, Publish Ahead of Print, 1781-1787.	0.6	3
110	Computational modeling of the immune response in multiple sclerosis using epimod framework. <i>BMC Bioinformatics</i> , 2020, 21, 550.	1.2	9

#	ARTICLE	IF	CITATIONS
111	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097522.	1.5	5
112	Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102567.	0.9	6
113	The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study. <i>Advances in Therapy</i> , 2020, 37, 2999-3009.	1.3	13
114	Consensus recommendations for family planning and pregnancy in multiple sclerosis in argentina. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102147.	0.9	7
115	Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. <i>European Journal of Neurology</i> , 2020, 27, 2047-2055.	1.7	18
116	<p>BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT<sup>Â</sup></p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 771-779.	0.8	4
117	Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852091793.	1.4	5
118	Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102158.	0.9	8
119	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
120	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
122	Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region. <i>Neurology and Therapy</i> , 2020, 9, 265-280.	1.4	18
123	Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102146.	0.9	23
124	Gadolinium should always be used to assess disease activity in MS â€“ Yes. <i>Multiple Sclerosis Journal</i> , 2020, 26, 765-766.	1.4	9
125	The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. <i>Cells</i> , 2020, 9, 1396.	1.8	17
126	An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1399-1405.	0.9	12
127	Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0231722.	1.1	3
128	Autologous Hematopoietic Stem Cell Transplantation (AHSCT): Standard of Care for Relapsing-Remitting Multiple Sclerosis Patients. <i>Neurology and Therapy</i> , 2020, 9, 197-203.	1.4	12
129	Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. <i>The Cochrane Library</i> , 0, , .	1.5	3

#	ARTICLE	IF	CITATIONS
130	Rethinking multiple sclerosis treatment strategies. <i>Lancet Neurology</i> , The, 2020, 19, 281-282.	4.9	8
131	Epidemiology of multiple sclerosis in Central Europe, update from Hungary. <i>Brain and Behavior</i> , 2020, 10, e01598.	1.0	13
132	Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642091031.	1.5	17
133	Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis. <i>BMC Neurology</i> , 2020, 20, 105.	0.8	45
134	Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732091077.	0.5	7
135	Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) – preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial. <i>BMC Neurology</i> , 2020, 20, 75.	0.8	10
136	Disease-modifying therapy aids cognition in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020, 16, 525-526.	4.9	7
137	Medication adherence/persistence among patients with active multiple sclerosis in Finland. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 605-612.	1.0	23
138	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093501.	1.5	23
139	Initial high-efficacy disease-modifying therapy in multiple sclerosis. <i>Neurology</i> , 2020, 95, e1041-e1051.	1.5	83
140	Therapeutic status quo in patients with relapsing-remitting multiple sclerosis: A sign of poor self-perception of their clinical status?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102354.	0.9	4
141	Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis. <i>BMC Medical Research Methodology</i> , 2020, 20, 24.	1.4	18
142	Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. <i>Postgraduate Medicine</i> , 2020, 132, 368-376.	0.9	6
143	Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. <i>Journal of Neurology</i> , 2020, 267, 1715-1723.	1.8	47
144	Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift®). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101948.	0.9	4
145	Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity. <i>Medicina (Lithuania)</i> , 2020, 56, 49.	0.8	22
146	Daphnetin Ameliorates Experimental Autoimmune Encephalomyelitis Through Regulating Heme Oxygenase-1. <i>Neurochemical Research</i> , 2020, 45, 872-881.	1.6	19
147	Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101956.	0.9	18

#	ARTICLE	IF	CITATIONS
148	Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. <i>Journal of Medical Economics</i> , 2020, 23, 484-491.	1.0	7
149	Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. <i>Journal of Drug Assessment</i> , 2020, 9, 20-36.	1.1	40
150	World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application. <i>Multiple Sclerosis Journal</i> , 2020, 26, 153-158.	1.4	5
151	Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102031.	0.9	5
152	Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. <i>Neurological Sciences</i> , 2020, 41, 2939-2945.	0.9	8
153	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. <i>CNS Drugs</i> , 2020, 34, 535-543.	2.7	6
154	Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs. <i>BioResearch Open Access</i> , 2020, 9, 94-105.	2.6	17
155	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102124.	0.9	18
156	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. <i>Annals of Neurology</i> , 2020, 88, 93-105.	2.8	79
157	Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community. <i>European Journal of Neurology</i> , 2020, 27, 1250-1256.	1.7	1
158	Pregnancy with multiple sclerosis. <i>Revue Neurologique</i> , 2021, 177, 180-194.	0.6	23
159	Clinical and genetic update of hereditary spastic paraparesis. <i>Revue Neurologique</i> , 2021, 177, 550-556.	0.6	22
160	High-Efficacy Disease-Modifying Therapies in People with Relapsingâ€Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions. <i>Patient</i> , 2021, 14, 241-248.	1.1	2
161	Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?. <i>Drug Discovery Today</i> , 2021, 26, 416-428.	3.2	16
162	Retrospective evaluation of regional telemedicine team meetings for multiple sclerosis (MS) patients: Experience from the Caen MS expert center in Normandy, France. <i>Revue Neurologique</i> , 2021, 177, 407-413.	0.6	3
163	Current and emerging diseaseâ€modulatory therapies and treatment targets for multiple sclerosis. <i>Journal of Internal Medicine</i> , 2021, 289, 771-791.	2.7	45
164	Living with secondary progressive multiple sclerosis in Europe: perspectives of multiple stakeholders. <i>Neurodegenerative Disease Management</i> , 2021, 11, 9-19.	1.2	3
165	Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: A systematic review. <i>Complementary Therapies in Medicine</i> , 2021, 56, 102595.	1.3	15

#	ARTICLE	IF	CITATIONS
166	Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102591.	0.9	8
167	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 347-359.	1.4	41
168	Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110019.	1.5	2
170	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110396.	1.5	86
171	Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1852-1863.	1.4	13
172	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	1.5	48
173	The Potential Preventive Effect of Pregnancy and Breastfeeding on Multiple Sclerosis. <i>European Neurology</i> , 2021, 84, 71-84.	0.6	4
174	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
175	Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 691-697.	0.2	9
176	Demyelinating Diseases. , 2021, , 313-351.		1
177	Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110015.	0.5	4
178	Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 149-158.	0.8	3
179	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 556-562.	0.9	7
181	Ozanimod for relapsing-remitting multiple sclerosis. <i>The Cochrane Library</i> , 0, , .	1.5	0
182	Ozanimod in relapsing forms of multiple sclerosis: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 143-149.	0.3	0
183	Prevalence of multiple sclerosis in key cities of Brazil. A study in Joinville, Southern Brazil. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 122-126.	0.3	2
184	Rituximab for people with multiple sclerosis. <i>The Cochrane Library</i> , 0, , .	1.5	0
186	Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis. <i>Current Neuropharmacology</i> , 2021, 19, 1966-1983.	1.4	9

#	ARTICLE	IF	CITATIONS
187	Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. <i>Journal of Immunology</i> , 2021, 206, 1454-1468.	0.4	50
188	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.	1.7	8
189	Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy. <i>Italian Journal of Pediatrics</i> , 2021, 47, 69.	1.0	3
190	Multiple Sclerosis Patient Management During the COVID-19 Pandemic: Practical Recommendations From the Portuguese Multiple Sclerosis Study Group (GEEM). <i>Frontiers in Neurology</i> , 2021, 12, 613769.	1.1	4
191	MRI findings in blinded trials should be available to treating physicians – Yes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 812-813.	1.4	1
192	Secondary progressive sclerosis in Russia, medical and social characteristics of patients and urgent tasks of therapy. <i>Medical Alphabet</i> , 2021, , 7-13.	0.0	1
193	Efficacy classification of modern therapies in multiple sclerosis. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 495-507.	0.6	59
194	Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018. <i>Frontiers in Neurology</i> , 2021, 12, 651511.	1.1	9
195	Feasibility, Acceptability, and Preliminary Validity of Self-Report Dietary Assessment in Adults with Multiple Sclerosis: Comparison with Doubly Labeled Water Measured Total Energy Expenditure. <i>Nutrients</i> , 2021, 13, 1198.	1.7	3
196	Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102747.	0.9	4
197	Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 123.	1.5	6
198	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1543-1555.	1.4	33
199	CLICK-MS and MASTER-2 Phase IVÂtrial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2021, 11, 99-111.	1.2	4
200	Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates. <i>Neurology and Therapy</i> , 2021, 10, 435-454.	1.4	2
201	Digital Twins for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 669811.	2.2	108
202	Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use. <i>CNS Drugs</i> , 2021, 35, 691-700.	2.7	12
203	Network Damage Predicts Clinical Worsening in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	16
204	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. <i>Neurology</i> , 2021, 97, e403-e413.	1.5	10

#	ARTICLE	IF	CITATIONS
205	Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021, 34, 598-603.	1.8	16
206	Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. <i>Journal of Neurology</i> , 2022, 269, 913-922.	1.8	13
209	Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1135-1144.	0.7	1
210	Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?. <i>Frontiers in Immunology</i> , 2021, 12, 661882.	2.2	36
211	Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. <i>Neurotherapeutics</i> , 2021, 18, 1657-1664.	2.1	13
212	Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program. <i>Neurology: Clinical Practice</i> , 2022, 12, 36-42.	0.8	1
213	A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile. <i>Pharmacoeconomics - Open</i> , 2021, 5, 635-647.	0.9	3
214	Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 598-606.	0.3	1
215	Quality of Care for Patients With Multiple Sclerosis—A Review of Existing Quality Indicators. <i>Frontiers in Neurology</i> , 2021, 12, 708723.	1.1	2
216	Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. <i>BMC Neurology</i> , 2021, 21, 324.	0.8	8
217	Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	2
218	Factors determining the treatment ineffectiveness in multiple sclerosis. <i>Neurological Research</i> , 2021, , 1-9.	0.6	0
219	The effectiveness of natalizumab vs fingolimod—A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
220	Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. <i>Neurological Research and Practice</i> . 2021, 3, 45.	1.0	7
221	Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis. <i>Value in Health</i> , 2021, 24, 1612-1619.	0.1	10
222	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103076.	0.9	13
223	Non-ambulatory measures of lower extremity sensorimotor function are associated with walking function in Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103051.	0.9	0
224	Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 241-246.	0.7	2

#	ARTICLE	IF	CITATIONS
225	Comparative effectiveness of dimethyl fumarate in multiple sclerosis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1268-1278.	1.1	6
226	Factors associated with fingolimod rebound: A single center real-life experience. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103278.	0.9	10
227	Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103091.	0.9	2
228	Health economics of disease-modifying therapy for multiple sclerosis in the United States. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642098703.	1.5	31
229	Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 463.	1.0	6
230	Diffusion basis spectrum imaging measures anti-inflammatory and neuroprotective effects of fingolimod on murine optic neuritis. <i>NeuroImage: Clinical</i> , 2021, 31, 102732.	1.4	4
231	Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis. <i>Drugs</i> , 2021, 81, 157-168.	4.9	20
232	Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? Synthesis. <i>Revue Neurologique</i> , 2020, 176, 490-493.	0.6	1
233	Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs. <i>RSC Drug Discovery Series</i> , 2019, , 1-32.	0.2	6
235	Fingolimod in multiple sclerosis: profile of use in habitual practice. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, 346-349.	0.5	4
236	Recommendations from the Expert Meeting Â«Secondary progressive multiple sclerosis: unresolved issues and prospectsÂ». <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019, 11, 172-175.	0.2	4
239	Multiple sclerosis. <i>Mental Health Clinician</i> , 2019, 9, 349-358.	0.5	12
240	Bewältigung und Umgang mit chronischen Krankheiten. <i>The Springer Reference Pflegegerapie, Gesundheit</i> , 2021, , 1-11.	0.2	0
241	Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1032.	1.1	5
242	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 1670-1677.	1.8	39
243	Clinical Pathway for the Diagnosis and Management of Patients With Relapsing-Remitting Multiple Sclerosis: A First Proposal for the Peruvian Population. <i>Frontiers in Neurology</i> , 2021, 12, 667398.	1.1	1
244	Multiple sclerosis by phenotype in Germany. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 57, 103326.	0.9	13
245	B Cell-based Therapies for Multiple Sclerosis. <i>RSC Drug Discovery Series</i> , 2019, , 134-169.	0.2	1

#	ARTICLE	IF	CITATIONS
246	Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis. <i>Medicinski Podmladak</i> , 2019, 70, 53-57.	0.2	1
247	Bewältigung und Umgang mit chronischen Krankheiten. <i>The Springer Reference Pflege, Therapie, Gesundheit</i> , 2019, , 311-321.	0.2	2
249	Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis. <i>Neurologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019, 11, 59-65.	0.2	0
250	A new era of multiple sclerosis treatment. <i>Neurologie Pro Praxi</i> , 2019, 20, 292-295.	0.0	0
251	Mechanisms of Autoimmunity and Pharmacologic Treatments. , 2020, , 207-249.		1
252	Analysis of the availability of therapy for multiple sclerosis with immunomodulators and immunosuppressants in Ukraine. <i>Management Economy and Quality Assurance in Pharmacy</i> , 2019, .	0.1	1
253	Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis. <i>Neurologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019, 11, 166-171.	0.2	0
255	Coexistence of multiple sclerosis and brain tumors: a literature review.. <i>Medicni Perspektivi</i> , 2020, 25, 30-36.	0.1	0
256	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. <i>Neurology and Therapy</i> , 2022, 11, 39-49.	1.4	12
257	Efficacy of transcranial direct current stimulation in people with multiple sclerosis: a review. <i>European Journal of Neurology</i> , 2022, 29, 648-664.	1.7	9
260	SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting. <i>Heliyon</i> , 2020, 6, e05819.	1.4	1
262	The Dilemma of When to Stop Disease-Modifying Therapy in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2020, 22, 75-84.	0.4	5
263	Rituximab for people with multiple sclerosis. <i>The Cochrane Library</i> , 2021, 2021, CD013874.	1.5	9
264	Measuring the effects of nurse practitioner (NP)-led care on depression and anxiety levels in people with multiple sclerosis: a study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 785.	0.7	2
265	Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2021, 11, e051509.	0.8	1
266	Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102433.	0.9	1
267	Impact of an Existential-Spiritual Intervention Compared with a Cognitive-Behavioral Therapy on Quality of Life and Meaning in Life among Women with Multiple Sclerosis. <i>Iranian Journal of Psychiatry</i> , 2020, 15, 322-330.	0.4	1
268	Association between multiple sclerosis and dietary patterns based on the traditional concept of food nature: a case-control study in Iran. <i>BMC Neurology</i> , 2021, 21, 453.	0.8	5

#	ARTICLE	IF	CITATIONS
269	Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. <i>Current Neuropharmacology</i> , 2022, 20, 1978-1987.	1.4	5
270	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 1001-1011.	4.9	36
271	Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 799380.	2.2	10
272	Electrical modeling of nerve fibers infected by multiple sclerosis disease. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
273	Impact of an Existential-Spiritual Intervention Compared with a Cognitive-Behavioral Therapy on Quality of Life and Meaning in Life among Women with Multiple Sclerosis. <i>Iranian Journal of Psychiatry</i> , 2020, 15, 322-330.	0.4	3
274	The need for a strategic therapeutic approach: multiple sclerosis in check. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232110630.	1.1	14
275	Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2022, Volume 12, 1-21.	0.7	3
276	Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score. <i>Frontiers in Neurology</i> , 2021, 12, 766956.	1.1	5
277	Effective rehabilitation interventions and participation among people with multiple sclerosis: An overview of reviews. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101529.	1.1	18
278	Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 105-114.	1.3	1
279	Self-perceived versus physician documented adverse events in patients with multiple sclerosis REGIMS - a pharmacovigilance registry for patients with multiple sclerosis in Germany. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103684.	0.9	0
280	Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210857.	0.5	2
281	Real-World Operation of Multiple Sclerosis Centres in Central-Eastern European Countries Covering 107 Million Inhabitants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
282	Ocrelizumab: A Review in Multiple Sclerosis. <i>Drugs</i> , 2022, 82, 323-334.	4.9	35
283	Do Hungarian multiple sclerosis care units fulfil international criteria?. <i>PLoS ONE</i> , 2022, 17, e0264328.	1.1	4
284	Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. <i>Frontiers in Immunology</i> , 2022, 13, 852563.	2.2	18
285	Identifying unanswered questions and setting the agenda for future systematic research in Multiple Sclerosis. A worldwide, multi-stakeholder Priority Setting project. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103688.	0.9	3
286	Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap. <i>Neurodegenerative Disease Management</i> , 2022, , .	1.2	3

#	ARTICLE	IF	CITATIONS
287	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	1.4	19
288	The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort. Multiple Sclerosis and Related Disorders, 2022, 61, 103759.	0.9	3
289	Immunopathophysiologic basis of multiple sclerosis and implications for therapy-a narrative review. Pharmacy & Pharmacology International Journal, 2021, 9, 263-271.	0.1	0
290	Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain. PLoS ONE, 2021, 16, e0261050.	1.1	4
291	Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs, 2022, 82, 55-62.	4.9	24
293	Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. International Journal of MS Care, 2022, 24, 90-97.	0.4	4
294	Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	1.1	4
295	Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review. Frontiers in Neurology, 2022, 13, 851413.	1.1	8
296	Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS). Current Reviews in Clinical and Experimental Pharmacology, 2023, 18, 39-50.	0.4	3
297	Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Multiple Sclerosis and Related Disorders, 2022, 63, 103805.	0.9	2
300	Cladribine Tablets for Relapsing/Remitting Multiple Sclerosis: A Clinician's Review. Neurology and Therapy, 2022, 11, 571-595.	1.4	22
301	Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies. Journal of the Medical Library Association: JMLA, 2022, 110, 185-204.	0.6	3
302	Proteomics in Multiple Sclerosis: The Perspective of the Clinician. International Journal of Molecular Sciences, 2022, 23, 5162.	1.8	15
303	Prognostic value of intrathecal IgM synthesis determined by various laboratory methods in patients with early multiple sclerosis - a prospective observational study. Multiple Sclerosis and Related Disorders, 2022, 63, 103847.	0.9	2
304	Multiple Sklerose. , 2021, , 47-59.		0
305	Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. Journal of Clinical Medicine, 2022, 11, 2807.	1.0	23
306	An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, , .	0.1	0
307	Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis. Neurology, 2022, 99, .	1.5	6

#	ARTICLE	IF	CITATIONS
308	Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Preference and Adherence, 0, Volume 16, 1307-1319.	0.8	4
309	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	1.8	32
310	Disability progression in multiple sclerosis patients using early first-line treatments. European Journal of Neurology, 2022, 29, 2761-2771.	1.7	4
311	Fampridin Antotoksikasyonu: Olgu Sunumu. Eurasian Journal of Toxicology, 0, , .	0.3	0
312	Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers. Frontiers in Neurology, 2022, 13, .	1.1	10
314	Therapeutic Advances in Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	28
315	Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America. Multiple Sclerosis and Related Disorders, 2022, 63, 103915.	0.9	5
316	Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 466-475.	4.9	25
317	Protocol for the treatment of patients with multiple sclerosis using bone marrow stromal cells (BMSC) in the State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine". Ukrain Kyi Visnyk Psykhonevrolohii, 2022, , 85-90.	0.0	0
318	Reparative inflammation in multiple sclerosis. Seminars in Immunology, 2022, 59, 101630.	2.7	2
319	Grey matter atrophy in patients with benign multiple sclerosis. Brain and Behavior, 2022, 12, .	1.0	8
320	An antagonistic monoclonal anti-Plexin-B1 antibody exerts therapeutic effects in mouse models of postmenopausal osteoporosis and multiple sclerosis. Journal of Biological Chemistry, 2022, 298, 102265.	1.6	3
321	The effect of nurse practitioner (NP-led) care on health-related quality of life in people with multiple sclerosis - a randomized trial. BMC Neurology, 2022, 22, .	0.8	3
323	Medical cannabis in multiple sclerosis. British Journal of Neuroscience Nursing, 2022, 18, S28-S31.	0.1	0
325	Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations. Multiple Sclerosis Journal, 0, , 135245852211162.	1.4	2
326	Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. Biomedicines, 2022, 10, 2041.	1.4	1
327	Anemoside B4 ameliorates experimental autoimmune encephalomyelitis in mice by modulating inflammatory responses and the gut microbiota. European Journal of Pharmacology, 2022, 931, 175185.	1.7	1
328	Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 68, 104138.	0.9	1

#	ARTICLE	IF	CITATIONS
329	The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study. <i>Advances in Therapy</i> , 2022, 39, 5072-5086.	1.3	2
330	Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study. <i>Zhurnal Nevrologii I Psikhiiatrii Imeni S S Korsakova</i> , 2022, 122, 96.	0.1	1
331	Analysis of Decisions on Incapacity for Work Issued at the Polish Social Insurance Institution (ZUS) in Relation to Persons with Multiple Sclerosis Before and After the Introduction of Current Drug Treatment Programmes for Multiple Sclerosis in Poland. <i>Acta Balneologica</i> , 2022, 64, 311-317.	0.1	0
332	Case Report Multiple Sclerosis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 142-145.	0.1	1
333	Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases. <i>Pharmaceuticals</i> , 2022, 15, 1077.	1.7	4
335	Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis. <i>Journal of Neurology</i> , 2023, 270, 413-422.	1.8	7
336	Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada. <i>PharmacoEconomics - Open</i> , 2022, 6, 859-870.	0.9	7
337	What are the trends in the treatment of multiple sclerosis in recent studies? â€“ A bibliometric analysis with global productivity during 1980â€“2021. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104185.	0.9	8
338	BewÃltigung und Umgang mit chronischen Krankheiten. <i>The Springer Reference Pflegegerapie, Gesundheit</i> , 2022, , 351-361.	0.2	0
339	Neurologic autoimmune diseases. , 2022, , 887-975.		0
340	Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211293.	1.5	4
341	Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	8
342	Diagnosis and treatment of progressive multiple sclerosis: A position paper. <i>European Journal of Neurology</i> , 2023, 30, 9-21.	1.7	4
343	Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic. <i>Journal of Neurology</i> , 0, , .	1.8	0
344	High-efficacy drugs in early stage of multiple sclerosis. <i>Neurologie Pro Praxi</i> , 2022, 23, 373-378.	0.0	0
345	Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 69, 104406.	0.9	0
346	Fertility preferences and unmet need for family planning in women with multiple sclerosis. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
347	MicroRNAs as a possible biomarker in the treatment of multiple sclerosis. <i>IBRO Neuroscience Reports</i> , 2022, 13, 492-499.	0.7	3

#	ARTICLE	IF	CITATIONS
348	High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsingâ€“Remitting Multiple Sclerosis. <i>CNS Drugs</i> , 2022, 36, 1285-1299.	2.7	20
349	Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. <i>Neurology and Therapy</i> , 2023, 12, 25-37.	1.4	5
350	Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial â€“ The problem of generalizability. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 69, 104422.	0.9	0
351	Current Issues in Multiple Sclerosis: Selected Highlights of theECTRIMS 2018 Congress. <i>European Medical Journal Neurology</i> , 0, , 2-9.	0.0	0
352	Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14578.	1.8	0
353	Multiple Sclerosis in Pregnancy: A Commentary on Disease Modification and Symptomatic Drug Therapies. <i>Neurology and Therapy</i> , 2023, 12, 1-10.	1.4	1
354	Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study. <i>BMC Neurology</i> , 2022, 22, .	0.8	0
355	Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. <i>PharmacoEconomics - Open</i> , 2023, 7, 229-241.	0.9	2
357	The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus. <i>Neurology and Therapy</i> , 0, , .	1.4	4
358	Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system. <i>Multiple Sclerosis Journal</i> , 0, , 135245852211391.	1.4	2
359	Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain. <i>Journal of Medical Economics</i> , 2023, 26, 11-18.	1.0	0
360	Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses. <i>Clinical and Translational Neuroscience</i> , 2022, 6, 27.	0.4	1
361	Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy. <i>Therapeutic Advances in Drug Safety</i> , 2023, 14, 204209862211438.	1.0	2
362	Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice. <i>Revue Neurologique</i> , 2023, 179, 256-264.	0.6	2
363	Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2023, 9, 205521732211503.	0.5	3
365	Costâ€“effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	0.6	1
366	Expert opinion on the pharmacological management of multiple sclerosis in women of childbearing age in Iraq. <i>Heliyon</i> , 2023, 9, e13350.	1.4	0
367	Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 718-725.	0.9	2

#	ARTICLE	IF	CITATIONS
368	Transcriptional regulatory network associated with multiple sclerosis pathogenesis. , 2023, , 359-368.		0
369	Synergy between health technology assessments and clinical guidelines for multiple sclerosis. Clinical and Translational Science, 2023, 16, 835-849.	1.5	3
370	Results of treatment with alemtuzumab in a Spanish cohort of patients with multiple sclerosis in the real world: The RealMS study. Frontiers in Neurology, 0, 14, .	1.1	1
371	Longitudinal Optical Coherence Tomography Measurement of Retinal Ganglion Cell and Nerve Fiber Layer to Assess Benign Course in Multiple Sclerosis. Journal of Clinical Medicine, 2023, 12, 2240.	1.0	0
372	Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Frontiers in Immunology, 0, 14, .	2.2	15
373	Exploring physiciansâ€™ prescribing behavior in patients with multiple sclerosis in Saudi Arabia: a sequential explanatory mixed-methods. BMC Neurology, 2023, 23, .	0.8	0
374	Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Multiple Sclerosis Journal, 0, , 135245852311614.	1.4	5
375	Multiple Sclerosis: A Review with a Focus on the Middle East and North Africa Region. , 2023, , 1-22.		0
376	High efficacy treatment since the first attack - an important step in the treatment of multiple sclerosis?. Neurologie Pro Praxi, 2023, 24, 40-44.	0.0	2
377	Validity of an inertial sensor-based system for the assessment of spatio-temporal parameters in people with multiple sclerosis. Frontiers in Neurology, 0, 14, .	1.1	3
400	Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis. CNS Drugs, 2023, 37, 849-866.	2.7	1
401	Transverse myelitis in children and adults. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 101-117.	1.0	0
403	No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]. Neurology and Therapy, 0, , .	1.4	0
422	Available Treatment Modules for Brain Disorders. Food Bioactive Ingredients, 2023, , 111-148.	0.3	0
424	Multiple sclerosis: time for early treatment with high-efficacy drugs. Journal of Neurology, 2024, 271, 105-115.	1.8	2
438	Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry. Journal of Neurology, 2024, 271, 1150-1159.	1.8	1
445	Disease-modifying therapies. , 2024, , 135-206.		0
446	Multiple sclerosis and pregnancy management. , 2024, , 237-265.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------